Genesis Unicorn Capital C... (GENQ)
10.47
2.03 (24.05%)
At close: Nov 14, 2024, 9:00 PM
Company Description
Genesis Unicorn Capital Corp. does not have significant operations.
It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other similar business combination with one or more businesses in biotech and pharmaceutical-focused companies, businesses, or assets.
The company was incorporated in 2021 and is based in Princeton, New Jersey.
Genesis Unicorn Capital Corp.
| Country | United States |
| IPO Date | Apr 7, 2022 |
| Industry | Shell Companies |
| Sector | Financial Services |
| Employees | n/a |
| CEO | Dr. Adeoye Y. Olukotun M.D., M.P.H. |
Contact Details
Address: 281 Witherspoon Street Princeton, New Jersey United States | |
| Website | n/a |
Stock Details
| Ticker Symbol | GENQ |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001853112 |
| CUSIP Number | 37187C100 |
| ISIN Number | US37187C1009 |
| Employer ID | 00-0000000 |
| SIC Code | 6770 |
Key Executives
| Name | Position |
|---|---|
| Dr. Adeoye Y. Olukotun M.D., M.P.H. | Chief Executive Officer |
| Hin Weng Lui | Pres, Chief Financial Officer & Director |
| Juan Fernandez Pascual | Chief Operating Officer |
| Dr. Niel Starksen M.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Feb 05, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Sep 08, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 03, 2023 | 25-NSE | Filing |
| Jul 27, 2023 | 8-K | Current Report |
| Jul 27, 2023 | 8-K | Current Report |
| Jul 26, 2023 | 8-K | Current Report |
| Jul 05, 2023 | DEFM14A | Filing |
| May 23, 2023 | 425 | Filing |